10:38 AM EST - Oncolytics Biotech Inc : Today announced third quarter financial results and operational highlights. Highlights include BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study. Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohort. Oncolytics Biotech Inc
shares T.ONC are trading down one cent at $1.48.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACC&qmodStoryID=5596424889115577
